Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Other financing activities (2016 - 2024)

Historic Other financing activities for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 15 years, with Q2 2024 value amounting to $107000.0.

  • Lifecore Biomedical, Inc. \De\'s Other financing activities fell 9550.61% to $107000.0 in Q2 2024 from the same period last year, while for May 2025 it was $6.2 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $435000.0 for FY2025, which is 8831.17% up from last year.
  • As of Q2 2024, Lifecore Biomedical, Inc. \De\'s Other financing activities stood at $107000.0, which was down 9550.61% from $2.4 million recorded in Q2 2023.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Other financing activities peaked at $8.4 million during Q1 2021, and registered a low of $37000.0 during Q1 2022.
  • Moreover, its 5-year median value for Other financing activities was $725000.0 (2020), whereas its average is $1.7 million.
  • As far as peak fluctuations go, Lifecore Biomedical, Inc. \De\'s Other financing activities tumbled by 9955.84% in 2022, and later surged by 981621.62% in 2023.
  • Lifecore Biomedical, Inc. \De\'s Other financing activities (Quarter) stood at $725000.0 in 2020, then crashed by 81.79% to $132000.0 in 2021, then surged by 393.94% to $652000.0 in 2022, then soared by 265.18% to $2.4 million in 2023, then tumbled by 95.51% to $107000.0 in 2024.
  • Its Other financing activities stands at $107000.0 for Q2 2024, versus $2.4 million for Q2 2023 and $3.7 million for Q1 2023.